

I. Requirements for Prior Authorization of Progestational Agents

A. <u>Prescriptions That Require Prior Authorization</u>

Prescriptions for Progestational Agents that meet any of the following conditions must be prior authorized:

1. A non-preferred Progestational Agent. See the Preferred Drug List (PDL) for the list of preferred Progestational Agents at: https://papdl.com/preferred-drug-list.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Progestational Agent, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

- 1. For a non-preferred Progestational Agent, **one** of the following:
 - Has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Progestational Agents approved or medically accepted for the beneficary's indication
 - For an intravaginal Progestational Agent, is prescribed the intravaginal Progestational Agent for treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration-approved package labeling OR a medically accepted indication, excluding use to promote fertility,

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Progestational Agent. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.



Highmark Wholecare Pharmacy Division Phone 800-392-1147 Fax 888-245-2049

NON-PREFERRED MEDICATION PRIOR AUTHORIZATION FORM (form effective 01/01/20)

☐New request	Renewal request	# of pages:	Prescriber name:				
Name of office contact:			Specialty:				
Contact's phone number:			NPI: State license #:				
LTC facility contact/phone:			Street address:				
Beneficiary name:			Suite #:	City/State/Z	City/State/Zip:		
Beneficiary ID#:		DOB:	Phone:		Fax:		
Please refer to https://papdl.com/preferred-drug-list for the list of preferred and non-preferred medications in each Preferred Drug List class.							
Non-preferred medication name:				Dosage form:	•		
Directions:			Quantity:	Refills:			
Diagnosis (submit o			Dx code (required	<i>t</i>):			
Has the beneficiary taken the requested non-preferred medication in the past 90 days? (submit documentation)							
Treatment failure or inadequate response with preferred medication(s) (include drug name, dose, and start/stop dates): Unacceptable side effects, hypersensitivities, or other intolerances to preferred medication(s) (include description and drug name(s)): Contraindication to preferred medication(s) (include description and drug name(s)): Unique clinical or age-specific indications supported by FDA approval or medical literature (describe):							
Absence of preferred medication(s) with appropriate formulation (list medical reason formulation is required):							
□ Drug-drug interaction with preferred medication(s) (describe):							
Other medical reason(s) the beneficiary cannot use the preferred medication(s) (describe):							
For renewal requests of previously approved medications, submit documentation of tolerability and beneficiary's clinical response.							
PLEASE FAX COMPLETED FORM TO HIGHMARK WHOLECARE – PHARMACY DIVISION							
Prescriber Signatu	ure:			Date:			

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.